Annals of dermatology

Korean Dermatological Association (대한피부과학회)
권호 표지
DOI QR코드

DOI QR Code

A Pilot Study to Evaluate the Efficacy and Safety of Treatment with Botulinum Toxin in Patients with Recalcitrant and Persistent Erythematotelangiectatic Rosacea

  • Park, Kui Young (Department of Dermatology, Chung-Ang University College of Medicine) ;
  • Kwon, Hyun Jung (Department of Dermatology, Chung-Ang University College of Medicine) ;
  • Kim, Jae Min (Department of Dermatology, Chung-Ang University College of Medicine) ;
  • Jeong, Guk Jin (Department of Dermatology, Chung-Ang University College of Medicine) ;
  • Kim, Beom Joon (Department of Dermatology, Chung-Ang University College of Medicine) ;
  • Seo, Seong Jun (Department of Dermatology, Chung-Ang University College of Medicine) ;
  • Kim, Myeong Nam (Department of Dermatology, Chung-Ang University College of Medicine)
  • Received : 2018.02.12
  • Accepted : 2018.07.23
  • Published : 2018.12.01
⟨ Previous Next ⟩

Abstract

Background: There are few pharmacologic options to reduce erythema and flushing in patients with recalcitrant erythematotelangiectatic rosacea (ETR). We previously reported two cases of refractory flushing and erythema of rosacea that were successfully treated with intradermal botulinum toxin injection, and additional research is needed to prove the efficacy and safety of this treatment. Objective: To report the efficacy and safety of botulinum toxin injection as an aid in persistent erythema of rosacea patients. Methods: A total of 20 Korean patients with recalcitrant ETR were enrolled to receive treatment by injection of botulinum toxin. Patients received one treatment of intradermal botulinum toxin injection and were assessed 1, 2, 4, and 8 weeks after treatment. The severity of erythema and telangiectasia was investigated by a non-treating physician, and the Erythema Index (EI) was assessed by mexameter at each visit. Patient satisfaction and any adverse events were also assessed at each visit. Results: 17 patients completed all follow-up visits and were included in the analysis. Intradermal injection of botulinum toxin significantly reduced erythema severity and EI in ETR patients. Patients reported a satisfaction score of $2.94{\pm}0.56$ at 8 weeks after treatment. Except for three patients who discontinued the study early due to inconvenience of facial muscle paralysis, 17 patients participating in the final analysis did not report side effects except injection pain at the time of the procedure. Conclusion: Intradermal injection of botulinum toxin can be used as an effective and relatively safe adjuvant agent for recalcitrant and persistent erythema of ETR patients.

Keywords

Acknowledgement

Supported by : Meditox Inc.

References

  1. Schwab VD, Sulk M, Seeliger S, Nowak P, Aubert J, Mess C, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15:53-62. https://doi.org/10.1038/jidsymp.2011.6
  2. Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA. J Drugs Dermatol 2012; 11: e76-e79.
  3. Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea. Dermatol Surg 2015;41 Suppl 1:S9-S16. https://doi.org/10.1097/DSS.0000000000000277
  4. Shah AR. Use of intradermal botulinum toxin to reduce sebum production and facial pore size. J Drugs Dermatol 2008; 7:847-850.
  5. Oh YJ, Lee NY, Suh DH, Koh JS, Lee SJ, Shin MK. A split-face study using botulinum toxin type B to decrease facial erythema index. J Cosmet Laser Ther 2011;13:243-248. https://doi.org/10.3109/14764172.2011.613479
  6. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245-258. https://doi.org/10.1016/S0041-0101(99)00153-1
  7. Durham PL, Cady R, Cady R. Regulation of calcitonin generelated peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004;44:35-42. https://doi.org/10.1111/j.1526-4610.2004.04007.x
  8. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174:977-982. https://doi.org/10.1097/01.ju.0000169481.42259.54
  9. Gessert CE, Bamford JT. Measuring the severity of rosacea: a review. Int J Dermatol 2003;42:444-448. https://doi.org/10.1046/j.1365-4362.2003.01780.x
  10. Park KY, Hyun MY, Jeong SY, Kim BJ, Kim MN, Hong CK. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. Dermatology 2015;230:299-301. https://doi.org/10.1159/000368773
  11. Kellogg DL Jr, Pergola PE, Piest KL, Kosiba WA, Crandall CG, Grossmann M, et al. Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission. Circ Res 1995;77:1222-1228. https://doi.org/10.1161/01.RES.77.6.1222
  12. Kellogg DL Jr, Zhao JL, Wu Y, Johnson JM. Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans. J Appl Physiol (1985) 2012; 113:1512-1518. https://doi.org/10.1152/japplphysiol.00859.2012
  13. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013;69(6 Suppl 1):S15-S26. https://doi.org/10.1016/j.jaad.2013.04.045
  14. Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011;15:2-11. https://doi.org/10.1038/jidsymp.2011.7
  15. Drummond PD, Su D. Endothelial and axon reflex vasodilatation to acetylcholine in rosacea-affected skin. Arch Dermatol Res 2012;304:133-137. https://doi.org/10.1007/s00403-011-1177-1
  16. Kramer HH, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003;250:188-193. https://doi.org/10.1007/s00415-003-0971-x
  17. Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, et al. Botulinum toxin type A reduces capsaicinevoked pain and neurogenic vasodilatation in human skin. Pain 2007;130:76-83. https://doi.org/10.1016/j.pain.2006.10.030
  18. Seeliger S, Buddenkotte J, Schmidt-Choudhury A, Rosignoli C, Shpacovitch V, von Arnim U, et al. Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo. Am J Pathol 2010;177:2563-2575. https://doi.org/10.2353/ajpath.2010.090941
  19. Goswami C, Rademacher N, Smalla KH, Kalscheuer V, Ropers HH, Gundelfinger ED, et al. TRPV1 acts as a synaptic protein and regulates vesicle recycling. J Cell Sci 2010;123:2045-2057. https://doi.org/10.1242/jcs.065144
  20. Sulk M, Seeliger S, Aubert J, Schwab VD, Cevikbas F, Rivier M, et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol 2012;132:1253-1262. https://doi.org/10.1038/jid.2011.424
  21. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004;173:2909-2912. https://doi.org/10.4049/jimmunol.173.5.2909
  22. Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR, et al. Activation of TRPV1 mediates calcitonin generelated peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci 2009;29:4981-4992. https://doi.org/10.1523/JNEUROSCI.5490-08.2009
  23. Shimizu T, Shibata M, Toriumi H, Iwashita T, Funakubo M, Sato H, et al. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis 2012;48:367-378. https://doi.org/10.1016/j.nbd.2012.07.010
  24. Li X, Coffield JA. Structural and functional interactions between transient receptor potential vanilloid subfamily 1 and botulinum neurotoxin serotype A. PLos One 2016;11:e0143024. https://doi.org/10.1371/journal.pone.0143024
  25. Eshghi G, Khezrian L, Alirezaei P. Botulinum toxin A in treatment of facial flushing. Acta Med Iran 2016;54:454-457.

Cited by

  1. Rosacea treatments: Current standards and additional options vol.2, pp.6, 2018, https://doi.org/10.1002/der2.88